Search research articles
Contact Us
Filters
Showing results (11-20 of 36) with videos related to
Page
of 4
Sort By:
Current Oncology (Toronto, Ont.)
|
February 24, 2022
Upfront <i>DPYD</i> Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
Antoine Desilets, William McCarvill, Francine Aubin, et al.
Current Oncology (Toronto, Ont.)
|
November 26, 2025
Antibiotic Exposure Does Not Impact Anti-BRAF/Anti-MEK Targeted Therapy Outcome in Patients with Advanced Melanoma
Yu Shi Wang, Qing Yin Wang, Alexia Erika Moise, et al.
BMC Cancer
|
January 16, 2019
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
Houda Bahig, Francine Aubin, John Stagg, et al.
Journal for Immunotherapy of Cancer
|
August 4, 2025
Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial
Danial Khan Hadi, Kelly J Baines, Behnam Jabbarizadeh, et al.
Clinical Colorectal Cancer
|
February 28, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study
Iván Victoria Ruiz, Nataliya V Uboha, Rahima Jamal, et al.
Journal for Immunotherapy of Cancer
|
November 22, 2017
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis, et al.
Oral Oncology
|
November 25, 2023
Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma
Cecilia Hes, Antoine Desilets, Marion Tonneau, et al.
The Lancet. Oncology
|
August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kicinski, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, et al.
Oncoimmunology
|
July 14, 2022
<i>Helicobacter pylori</i> serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors
Marion Tonneau, Alexis Nolin-Lapalme, Suzanne Kazandjian, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 36) with videos related to
Sort By:
Page
of 4
Current Oncology (Toronto, Ont.)
|
February 24, 2022
Upfront <i>DPYD</i> Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
Antoine Desilets, William McCarvill, Francine Aubin, et al.
Current Oncology (Toronto, Ont.)
|
November 26, 2025
Antibiotic Exposure Does Not Impact Anti-BRAF/Anti-MEK Targeted Therapy Outcome in Patients with Advanced Melanoma
Yu Shi Wang, Qing Yin Wang, Alexia Erika Moise, et al.
BMC Cancer
|
January 16, 2019
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
Houda Bahig, Francine Aubin, John Stagg, et al.
Journal for Immunotherapy of Cancer
|
August 4, 2025
Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial
Danial Khan Hadi, Kelly J Baines, Behnam Jabbarizadeh, et al.
Clinical Colorectal Cancer
|
February 28, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study
Iván Victoria Ruiz, Nataliya V Uboha, Rahima Jamal, et al.
Journal for Immunotherapy of Cancer
|
November 22, 2017
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis, et al.
Oral Oncology
|
November 25, 2023
Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma
Cecilia Hes, Antoine Desilets, Marion Tonneau, et al.
The Lancet. Oncology
|
August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kicinski, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, et al.
Oncoimmunology
|
July 14, 2022
<i>Helicobacter pylori</i> serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors
Marion Tonneau, Alexis Nolin-Lapalme, Suzanne Kazandjian, et al.
Page
of 4